Strong PD-L1 expression in granulomatous prostatitis.
PD-L1
carcinoma
granulomatous prostatitis
lymphoepithelial lesions
prostatitis
Journal
The Prostate
ISSN: 1097-0045
Titre abrégé: Prostate
Pays: United States
ID NLM: 8101368
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
29
04
2023
received:
07
02
2023
accepted:
07
06
2023
medline:
18
8
2023
pubmed:
26
6
2023
entrez:
26
6
2023
Statut:
ppublish
Résumé
The expression of programmed cell death ligand protein (PD-L1) is weakly investigated in non-tumoral and inflammatory prostatic pathology. The diagnosis of granulomatous prostatitis (GP) rests on the recognition of localized or diffuse epithelioid granulomatous inflammation in prostatic tissue which is frequently difficult by conventional histological observation alone. PD-L1 expression in GP is not well studied so far. We studied PD-L1 expression in 17 GP cases (9 nonspecific GP, 5 Bacillus Calmette-Guérin induced prostatitis, 1 prostatic tuberculosis, and 3 cases of postsurgical prostatic granulomas). The control group included 10 radical prostatectomies of patients with high Gleason score prostate adenocarcinoma (PCa) and National Institutes of Health-category IV prostatitis (high-grade histologic prostatitis; HG-HP). All of the GP cases showed easily visible strong membranous PD-L1 expression (high levels of combined positive score) in localized and diffuse epithelioid granulomatous prostatic inflammation. None of the control cases showed the presence of significant PD-L1 expression in inflammatory infiltrates in HG-HP, tumor parenchyma, and stroma in PCa. The study presents the first attempt to examine PD-L1 expression in GP. Granulomatous inflammation in GP is easily identified when stained with PD-L1.
Sections du résumé
BACKGROUND
The expression of programmed cell death ligand protein (PD-L1) is weakly investigated in non-tumoral and inflammatory prostatic pathology. The diagnosis of granulomatous prostatitis (GP) rests on the recognition of localized or diffuse epithelioid granulomatous inflammation in prostatic tissue which is frequently difficult by conventional histological observation alone. PD-L1 expression in GP is not well studied so far.
METHODS
We studied PD-L1 expression in 17 GP cases (9 nonspecific GP, 5 Bacillus Calmette-Guérin induced prostatitis, 1 prostatic tuberculosis, and 3 cases of postsurgical prostatic granulomas). The control group included 10 radical prostatectomies of patients with high Gleason score prostate adenocarcinoma (PCa) and National Institutes of Health-category IV prostatitis (high-grade histologic prostatitis; HG-HP).
RESULTS
All of the GP cases showed easily visible strong membranous PD-L1 expression (high levels of combined positive score) in localized and diffuse epithelioid granulomatous prostatic inflammation. None of the control cases showed the presence of significant PD-L1 expression in inflammatory infiltrates in HG-HP, tumor parenchyma, and stroma in PCa.
CONCLUSIONS
The study presents the first attempt to examine PD-L1 expression in GP. Granulomatous inflammation in GP is easily identified when stained with PD-L1.
Substances chimiques
B7-H1 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1285-1289Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
O'Dea MJ, Hunting DB, Greene LF. Non-specific granulomatous prostatitis. J Urol. 1977;118:58-60.
Stillwell TJ, Engen DE, Farrow GM. The clinical spectrum of granulomatous prostatitis: a report of 200 cases. J Urol. 1987;138:320-323.
Epstein JI, Hutchins GM. Granulomatous prostatitis: distinction among allergic, nonspecific, and post-transurethral resection lesions. Hum Pathol. 1984;15:818-825.
Oppenheimer JR, Kahane H, Epstein JI. Granulomatous prostatitis on needle biopsy. Arch Pathol Lab Med. 1997;121:724-729.
Dikov D, Koleva M, Boivin JF, Lisner T, Belovezhdov V, Sarafian V. Histopathology of nonspecific granulomatous prostatitis with special reference to eosinophilic epithelial metaplasia: pathophysiologic, diagnostic and differential diagnostic correlations. Indian J Pathol Microbiol. 2020;63(suppl ment):34. doi:10.4103/IJPM.IJPM_568_18
Kubo T, Hirohashi Y, Tsukahara T, et al. Epithelioid granulomatous lesions express abundant programmed death ligand-1 (PD-L1): a discussion of adverse events in anti-PD-1 antibody-based cancer immunotherapy. Hum Vaccines Immunother. 2021;17:1940-1942. doi:10.1080/21645515.2020.1870364
Dikov D, Koleva M, Simitchiev K, Baltov M, Sarafian V. PD-L1 positive lympho-epithelial lesions in inflammatory prostate. Histol Histopathol. 2022;37:749-755. doi:10.14670/HH-18-479
Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704.
Martin AM, Nirschl TR, Nirschl CJ, et al. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer Prostatic Dis. 2015;18(4):325-332. doi:10.1038/pcan.2015.39
Haffner MC, Guner G, Taheri D, et al. Comprehensive evaluation of programmed death-ligand 1 expression in primary and metastatic prostate cancer. Am J Pathol. 2018;188(6):1478-1485. doi:10.1016/j.ajpath.2018.02.014
Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486-499. doi:10.1038/nri3862
Presti B, Weidner N. Granulomatous prostatitis and poorly differentiated prostate carcinoma. Their distinction with the use of immunohistochemical methods. Am J Clin Path. 1991;95:330-334.
Epstein JI, Egevad L, Humphrey PA, Montironi R, Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol. 2014;38(8):e6-e19. doi:10.1097/PAS.0000000000000238